{"entity":{"id":"idea-fund-flash-evidence-programme","kind":"idea","name":"A coordinated FLASH radiotherapy evidence programme with shared dose-rate standards","aka":[],"tldr":"Ultra-fast radiotherapy may spare healthy tissue while still killing tumours, but every centre is testing it differently. A coordinated programme would agree the measurements and run the trials that settle whether it works.","summary":"FLASH radiotherapy (dose delivered in under a second at ultra-high dose rate) shows a normal-tissue sparing effect in animals; the first human trial (FAST-01, proton FLASH for bone metastases) showed feasibility. Evidence is fragmented across manufacturers and centres with different beam types (electron, proton, photon prototypes), dose-rate definitions and dosimetry. The programme would fund a consortium to standardise dosimetry and dose-rate reporting, build a shared preclinical platform to define the biological conditions of the effect, and run coordinated multi-centre phase 2 and randomised trials in indications where normal-tissue toxicity limits cure (head and neck, thoracic, paediatric). Without coordination the field risks a decade of unconvincing small studies.","asOf":"2026-09-08","links":[{"label":"FAST-01 (NCT04592887)","url":"https://clinicaltrials.gov/study/NCT04592887"}],"tags":[],"related":["idea-fund-radiotherapy-trials-infrastructure","idea-fund-proton-coverage-with-evidence"],"cancers":["head-and-neck","nsclc"],"sections":[],"technologies":["flash-rt","proton-therapy"],"targets":[],"drugs":[],"companies":["varian","iba"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-surgery-radiation-innovation","b-toxicity-qol"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A coordinated programme produces, within six years, a randomised trial demonstrating whether FLASH reduces a pre-specified grade 3 or higher toxicity endpoint by at least a third at equal tumour control in a curative indication, settling the clinical question one way or the other.","rationale":"Preclinical FLASH sparing has been reproduced across species and tissues, but the mechanism and required beam parameters are debated; the history of proton therapy shows that letting technology diffuse before randomised evidence produces decades of unresolved argument. Coordinated dosimetry standards were what made IMRT and SBRT trials interpretable.","test":"Fund the consortium with mandatory shared dosimetry, complete a multi-centre phase 2 in one indication within three years, and launch a randomised trial with a toxicity primary endpoint.","maturity":"early-clinical","actor":"research","cost":"large","horizonYears":6},"route":"/ideas/idea-fund-flash-evidence-programme/","neighbours":{"idea":[{"id":"idea-fund-radiotherapy-innovation-pathway","kind":"idea","name":"A regulatory pathway for new radiotherapy techniques modelled on drug development","route":"/ideas/idea-fund-radiotherapy-innovation-pathway/"},{"id":"idea-fund-radiotherapy-trials-infrastructure","kind":"idea","name":"Core-funded radiotherapy trials infrastructure with central quality assurance","route":"/ideas/idea-fund-radiotherapy-trials-infrastructure/"},{"id":"idea-fund-proton-coverage-with-evidence","kind":"idea","name":"Pooled coverage-with-evidence for proton therapy across all centres","route":"/ideas/idea-fund-proton-coverage-with-evidence/"}],"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"flash-rt","kind":"technology","name":"FLASH radiotherapy","route":"/technologies/flash-rt/"},{"id":"proton-therapy","kind":"technology","name":"Proton therapy","route":"/technologies/proton-therapy/"}],"company":[{"id":"iba","kind":"company","name":"IBA (Ion Beam Applications)","route":"/companies/iba/"},{"id":"varian","kind":"company","name":"Varian (Siemens Healthineers)","route":"/companies/varian/"}],"bottleneck":[{"id":"b-surgery-radiation-innovation","kind":"bottleneck","name":"Surgery and radiotherapy cure most, get least","route":"/bottlenecks/b-surgery-radiation-innovation/"},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/"}]}}